Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
benztropine mesylate
Overview
What is benztropine mesylate?
Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.
It is designated chemically as 3∝-(Diphenylmethoxy)-1∝H, 5∝H-tropane methanesulfonate. Its molecular formula is CHNO•CHOS, and its structural formula is:
Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54.
Each benztropine mesylate tablet for oral administration contains benztropine mesylate 0.5 mg, 1 mg or 2 mg.
Inactive ingredients: croscarmellose sodium, anhydrous lactose, magnesium stearate, povidone.
What does benztropine mesylate look like?
What are the available doses of benztropine mesylate?
Sorry No records found.
What should I talk to my health care provider before I take benztropine mesylate?
Sorry No records found
How should I use benztropine mesylate?
For use as an adjunct in the therapy of all forms of parkinsonism.
Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see ) due to neuroleptic drugs (e.g., phenothiazines).
Benztropine mesylate tablets should be used when patients are able to take oral medication.
The injection is especially useful for psychotic patients with acute dystonic reactions or other reactions that make oral medication difficult or impossible. It is recommended also when a more rapid response is desired than can be obtained with the tablets.
Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.
What interacts with benztropine mesylate?
Hypersensitivity to benztropine mesylate tablets or to any component of the tablets.
Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.
What are the warnings of benztropine mesylate?
Array
Safe use in pregnancy has not been established.
Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.
Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.
What are the precautions of benztropine mesylate?
General
Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.
Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine mesylate.
The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.
Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.
Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate is not recommended for use in patients with tardive dyskinesia.
The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.
Drug Interactions
Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see ).
Pediatric Use
Because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see ).
What are the side effects of benztropine mesylate?
The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.
Cardiovascular
Digestive
If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.
Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.
Nervous System
Special Senses
Urogenital
Metabolic/Immune or Skin
Other
What should I look out for while using benztropine mesylate?
Hypersensitivity to benztropine mesylate tablets or to any component of the tablets.
Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.
Safe use in pregnancy has not been established.
Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.
Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.
What might happen if I take too much benztropine mesylate?
How should I store and handle benztropine mesylate?
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).Benztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central PharmacyBenztropine Mesylate Tablets, USP, for oral use, are supplied in the following forms:As 0.5 mg: Compressed tablet, white, 1/4" diameter, flat beveled edge; one side scored and debossed 832 and BM05, one side plain.As 1 mg: Compressed tablet, white, 0.231" x 0.420", oval; one side scored and debossed 832 and BM1, one side plain.As 2 mg: Compressed tablet, white, 9/32" diameter, flat beveled edge; one side scored and debossed 832 and BM2, one side plain.They are supplied by as follows:Store at controlled room temperature 15 - 30° C (59 - 86° F).Dispense in well-closed containers as defined in the USP.Keep out of reach of children.-------------------------*Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968.Manufactured by: UPSHER-SMITH LABORATORIES, INC. Minneapolis, MN 55447This Product was Repackaged By:State of Florida DOH Central Pharmacy
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.
In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.
In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.
Non-Clinical Toxicology
Hypersensitivity to benztropine mesylate tablets or to any component of the tablets.Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.
Safe use in pregnancy has not been established.
Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.
Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.
Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see ).
Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.
Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine mesylate.
The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.
Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.
Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate is not recommended for use in patients with tardive dyskinesia.
The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.
The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.
Cardiovascular
Digestive
If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.
Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.
Nervous System
Special Senses
Urogenital
Metabolic/Immune or Skin
Other
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
518Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).